+ New Watchlist

Benzinga Research

Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Free Stock Reports

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Government Trades

Perfect Stock Portfolio

Easy Income Portfolio

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

Comments

Loading...

Sanofi

SNYNASDAQ

Logo brought to you by Benzinga Data

Perks Buy Compare Brokers

Perks Buy Compare Brokers

$47.98

At close: Nov 21, 4:00 PM EDT

$47.98

00.00%

After Hours: 4:00 PM EDT

Sanofi (SNY) Forecast

News

Earnings Sanofi (SNY) Options Guidance Dividends Analyst Ratings Insider Trades Government Trades Short Interest

Latest news for Sanofi (NASDAQ:SNY) Stock

Sanofi Stock (NASDAQ: SNY)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Wednesday, November 20, 2024

Big Pharma's Pharmacy-Benefit Managers Accuse FTC of Overreach In Effort to Reshape Drug Rebate System
Vandana Singh
Mutated Bird Flu Case In California Puts Humans At Increased Risk, So Which Companies Are Developing Vaccines?
Hayden Buckfire

Monday, November 18, 2024

U.S. CDC Says Since April Confirmed Avian Inf...
Benzinga Newsdesk

Friday, November 15, 2024

European And US Vaccine Stocks Are Under Pressure - Here's WHy
Vandana Singh
FDA To Revisit Regeneron/Sanofi's Dupixent For Rare Skin Disease
Vandana Singh
Dupixent's sBLA Resubmission Accepted By FDA;...
Benzinga Newsdesk
Viking Fund Management Sells Big Oil Stocks In Q3, Cuts Tesla Position In Half, Adds To Largest Position Broadcom
Chris Katje

Thursday, November 14, 2024

Sarclisa Recommended For EU Approval By The C...
Benzinga Newsdesk

Wednesday, November 13, 2024

Regeneron/Sanofi's Dupixent Approval Signals Major Treatment Breakthrough For Smokers' Lung Disease
Vandana Singh
Humanitarian Organization Criticizes Eli Lilly, Novo Nordisk And Sanofi Of Having 'Double Standards' For High Insulin Price
Vandana Singh

Monday, November 11, 2024

MediciNova Says Notified By Sanofi That Sanof...
Benzinga Newsdesk

Friday, November 08, 2024

Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks
Vandana Singh

Wednesday, November 06, 2024

Regeneron And Sanofi's Dupixent Receives EU A...
Benzinga Newsdesk

Tuesday, November 05, 2024

Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On Efficacy, Analysts Say
Vandana Singh

Friday, November 01, 2024

FDA Panel Rejects Lexicon's Zynquista For Type 1 Diabetes
Vandana Singh

Thursday, October 31, 2024

Why Is Regeneron Pharmaceuticals Stock Trading Lower Today?
Vandana Singh

Wednesday, October 30, 2024

USDA Says H5N1 Bird Flu Detected In Swine For...
Benzinga Newsdesk
USDA To Begin Bulk Milk Testing For Bird Flu ...
Benzinga Newsdesk

Tuesday, October 29, 2024

US CDC Reports 36 H5 Bird Flu Cases In U.S. S...
Benzinga Newsdesk

Monday, October 28, 2024

Sanofi Says Beyfortus Will Be Broadly Availab...
Benzinga Newsdesk

Friday, October 25, 2024

Eli Lilly's Newly FDA-Approved Eczema Drug Improves Skin And Itch In Patients Previously Treated With Sanofi/Regeneron's Dupixent
Vandana Singh
Sanofi shares are trading higher after the co...
Benzinga Newsdesk
Sanofi Earns $5B Q3 Core Profit On Strong Dupixent And Vaccine Sales, Raises 2024 Forecast
Vandana Singh
Sanofi Upgrades 2024 Business EPS Guidance To...
Benzinga Newsdesk
Sanofi Q3 2024 Adj. EPS $1.57 Up From $1.39 Y...
Benzinga Newsdesk

Thursday, October 24, 2024

CDC Issues Report On Missouri H5N1 Serology T...
Benzinga Newsdesk
Sanofi's Earnings Outlook
Benzinga Insights
Regeneron And Sanofi To Present Phase 3 LIBER...
Benzinga Newsdesk

Monday, October 21, 2024

Sanofi Engages In Exclusive Talks With US Private Equity CD&R For Its Consumer Health Business
Vandana Singh
Sanofi Eyes Low Single-Digit EPS Growth For 2...
Benzinga Newsdesk
Sanofi And CD&R Enter Exclusive Talks To Shap...
Benzinga Newsdesk

Friday, October 18, 2024

'Sanofi Set to Sign Consumer Health Deal With...
Benzinga Newsdesk
European Medicines Agency's Panel Supports Approval Of Novartis' Kisqali In Patients With Early-Breast Cancer
Vandana Singh
France's PAI Partners Ups Bid for Sanofi's Consumer Health Division As French Government Hints Possible Regulatory Block
Vandana Singh

Thursday, October 17, 2024

Sanofi And Orano Med Team Up To Develop Next-...
Benzinga Newsdesk

Wednesday, October 16, 2024

Exscientia Announced The Advancement Of Two A...
Benzinga Newsdesk

Tuesday, October 15, 2024

Sanofi Might Face Political Hurdles In $16B Consumer Pharma Unit Sale To US Private Equity CD&R
Vandana Singh

Friday, October 11, 2024

State Reports Six Human Bird Flu Cases Now Co...
Benzinga Newsdesk
World's Third-Largest OTC Player Sanofi's Consumer Health Unit Nears $16B Deal With Clayton Dubilier & Rice
Vandana Singh
Sanofi Engages In Discussions To Sell 50% Con...
Benzinga Newsdesk

Thursday, October 10, 2024

Denali Therapeutics Stock Is Sliding After The Bell: Here's Why
Adam Eckert
'CD&R Nears €15 billion Deal for Sanofi Consu...
Benzinga Newsdesk

Wednesday, October 09, 2024

Sanofi Unveils Beyfortus Data At IDWeek 2024,...
Benzinga Newsdesk

Monday, October 07, 2024

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
Avi Kapoor

Friday, October 04, 2024

GSK, Sanofi, And CSL Secure US Government Fund To Boost Bird Flu Vaccine Production: Report
Vandana Singh
U.S. HHS Official Says BARDA Awarding Additio...
Benzinga Newsdesk
Sanofi Sells Global Rights To Rare Autoimmune Drug Enjaymo For $825M Upfront To Italian Firm Recordati
Vandana Singh
Novo Nordisk/AstraZeneca's Manufacturing Partner Thermo Fisher Questioned Over Manufacturing Lapses
Vandana Singh

Wednesday, October 02, 2024

World Organization For Animal Health Says Hun...
Benzinga Newsdesk

Tuesday, October 01, 2024

US HHS Reveal Cost Savings For 54 Prescription Drugs Including Novartis' Cancer Drug, Ozempic Could be Next
Vandana Singh

Create a Watchlist

FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.

People Also Watch

Popular Channels

PreMarket Prep
Press Releases
Analyst Ratings
News
Options
ETFs

Tools & Features

Real Time Feed
Public RSS Feeds
Submit News Tips
Blog
Embeddable Finance Widgets & Tools
Benzinga Catalyst

Partners & Contributors

Affiliate Program
Contributor Portal
Licensing & Syndication
Sponsored Content
Advertise With Us
Lead Generation & SEO

About Benzinga

About Us
Careers
In The News
Events
Contact Us

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2024 Benzinga | All Rights Reserved